Sandhill Capital Partners Decreased Its Blackbaud Com (BLKB) Position by $904,365; Palo Alto Investors Has Lifted Its Epizyme (EPZM) Stake by $13.30 Million as Share Value Rose

January 14, 2018 - By wolcottdaily

Sandhill Capital Partners Llc decreased its stake in Blackbaud Inc Com (BLKB) by 5.37% based on its latest 2017Q3 regulatory filing with the SEC. Sandhill Capital Partners Llc sold 10,395 shares as the company’s stock rose 9.41% with the market. The institutional investor held 183,240 shares of the technology company at the end of 2017Q3, valued at $16.09 million, down from 193,635 at the end of the previous reported quarter. Sandhill Capital Partners Llc who had been investing in Blackbaud Inc Com for a number of months, seems to be less bullish one the $4.49 billion market cap company. The stock increased 0.52% or $0.49 during the last trading session, reaching $95.55. About 123,405 shares traded. Blackbaud, Inc. (NASDAQ:BLKB) has risen 35.80% since January 14, 2017 and is uptrending. It has outperformed by 19.10% the S&P500.

William Leland Edwards increased its stake in Epizyme Inc (EPZM) by 12.28% based on its latest 2017Q3 regulatory filing with the SEC. Palo Alto Investors Llc bought 700,000 shares as the company’s stock rose 39.84% with the market. The hedge fund run by William Leland Edwards held 6.40 million shares of the health care company at the end of 2017Q3, valued at $121.89 million, up from 5.70 million at the end of the previous reported quarter. Palo Alto Investors Llc who had been investing in Epizyme Inc for a number of months, seems to be bullish on the $1.03 billion market cap company. The stock decreased 4.50% or $0.7 during the last trading session, reaching $14.85. About 482,600 shares traded. Epizyme, Inc. (NASDAQ:EPZM) has risen 91.85% since January 14, 2017 and is uptrending. It has outperformed by 75.15% the S&P500.

Investors sentiment decreased to 1.35 in 2017 Q3. Its down 0.07, from 1.42 in 2017Q2. It fall, as 21 investors sold BLKB shares while 59 reduced holdings. 29 funds opened positions while 79 raised stakes. 52.08 million shares or 0.90% less from 52.56 million shares in 2017Q2 were reported. Goldman Sachs Gp has 206,940 shares for 0% of their portfolio. Weaver C Barksdale & accumulated 49 shares or 0% of the stock. Tiverton Asset Mngmt Ltd Llc owns 0.02% invested in Blackbaud, Inc. (NASDAQ:BLKB) for 3,150 shares. Loomis Sayles Commerce LP stated it has 0.07% in Blackbaud, Inc. (NASDAQ:BLKB). Raymond James Svcs Advsrs holds 15,624 shares. Neuberger Berman Grp Ltd Llc owns 739,621 shares. Raymond James And Assoc stated it has 0% of its portfolio in Blackbaud, Inc. (NASDAQ:BLKB). Schaper Benz And Wise Invest Counsel Wi invested 0.13% in Blackbaud, Inc. (NASDAQ:BLKB). Moreover, Texas Permanent School Fund has 0.04% invested in Blackbaud, Inc. (NASDAQ:BLKB). Deutsche Bancorp Ag invested in 245,111 shares or 0.01% of the stock. Oregon Public Employees Retirement Fund has 0.03% invested in Blackbaud, Inc. (NASDAQ:BLKB). Fdx Advsr Incorporated reported 0.03% in Blackbaud, Inc. (NASDAQ:BLKB). Moreover, Janney Montgomery Scott Ltd Liability has 0% invested in Blackbaud, Inc. (NASDAQ:BLKB). Virginia Retirement Sys Et Al stated it has 0.02% of its portfolio in Blackbaud, Inc. (NASDAQ:BLKB). Veritable LP stated it has 6,755 shares or 0.01% of all its holdings.

Among 12 analysts covering Blackbaud Inc (NASDAQ:BLKB), 5 have Buy rating, 1 Sell and 6 Hold. Therefore 42% are positive. Blackbaud Inc had 25 analyst reports since October 13, 2015 according to SRatingsIntel. As per Friday, October 27, the company rating was maintained by Citigroup. Robert W. Baird initiated the shares of BLKB in report on Thursday, December 10 with “Outperform” rating. Robert W. Baird maintained Blackbaud, Inc. (NASDAQ:BLKB) on Monday, October 23 with “Neutral” rating. The firm earned “Neutral” rating on Tuesday, October 13 by B. Riley & Co. The firm earned “Buy” rating on Thursday, February 18 by Wunderlich. The rating was initiated by Benchmark on Thursday, November 19 with “Buy”. The firm has “Underperform” rating by Bank of America given on Wednesday, November 23. Wunderlich downgraded Blackbaud, Inc. (NASDAQ:BLKB) on Friday, February 10 to “Hold” rating. The firm has “Hold” rating given on Friday, September 29 by Robert W. Baird. The rating was maintained by Stifel Nicolaus with “Buy” on Thursday, October 26.

Since August 8, 2017, it had 0 insider buys, and 6 selling transactions for $1.77 million activity. $419,855 worth of Blackbaud, Inc. (NASDAQ:BLKB) was sold by MOONEY KEVIN W on Monday, August 21. On Tuesday, August 22 Nash Sarah E sold $93,682 worth of Blackbaud, Inc. (NASDAQ:BLKB) or 1,105 shares. The insider Gianoni Michael P sold 4,000 shares worth $351,080. $444,956 worth of Blackbaud, Inc. (NASDAQ:BLKB) was sold by Olson Jon W on Thursday, August 31.

Analysts await Blackbaud, Inc. (NASDAQ:BLKB) to report earnings on February, 14. They expect $0.44 EPS, down 12.00% or $0.06 from last year’s $0.5 per share. BLKB’s profit will be $20.68 million for 54.29 P/E if the $0.44 EPS becomes a reality. After $0.42 actual EPS reported by Blackbaud, Inc. for the previous quarter, Wall Street now forecasts 4.76% EPS growth.

Sandhill Capital Partners Llc, which manages about $570.29M and $513.36M US Long portfolio, upped its stake in Adobe Sys Inc Com (NASDAQ:ADBE) by 2,602 shares to 158,247 shares, valued at $23.61M in 2017Q3, according to the filing. It also increased its holding in Us Foods Hldg Corp Com by 13,761 shares in the quarter, for a total of 734,595 shares, and has risen its stake in Dolby Laboratories Inc Cl A (NYSE:DLB).

Since August 24, 2017, it had 1 insider buy, and 3 insider sales for $2.32 million activity. 15,000 shares were sold by Ho Peter Tai-Ching, worth $235,266 on Thursday, August 24.

Palo Alto Investors Llc, which manages about $1.30 billion and $2.37 billion US Long portfolio, decreased its stake in Abiomed Inc (NASDAQ:ABMD) by 15,984 shares to 1.94M shares, valued at $326.29M in 2017Q3, according to the filing. It also reduced its holding in Soleno Therapeutics Inc by 338,990 shares in the quarter, leaving it with 84,748 shares, and cut its stake in United Therapeutics Corp Del (NASDAQ:UTHR).

Investors sentiment decreased to 1.46 in Q3 2017. Its down 0.47, from 1.93 in 2017Q2. It turned negative, as 15 investors sold EPZM shares while 22 reduced holdings. 13 funds opened positions while 41 raised stakes. 58.04 million shares or 22.28% more from 47.46 million shares in 2017Q2 were reported. California Pub Employees Retirement System owns 135,500 shares or 0% of their US portfolio. Swiss Financial Bank reported 83,700 shares. State Common Retirement Fund has 0% invested in Epizyme, Inc. (NASDAQ:EPZM). Price T Rowe Associates Md invested in 14,712 shares or 0% of the stock. Ameritas Invest Inc stated it has 0% of its portfolio in Epizyme, Inc. (NASDAQ:EPZM). 700,526 are held by Deerfield Comm. Alliancebernstein LP stated it has 0% of its portfolio in Epizyme, Inc. (NASDAQ:EPZM). Bain Public Equity Ltd Limited Liability Company owns 180,574 shares for 0.22% of their portfolio. Jpmorgan Chase Com holds 0% or 158,400 shares in its portfolio. Switzerland-based Credit Suisse Ag has invested 0% in Epizyme, Inc. (NASDAQ:EPZM). State Board Of Administration Of Florida Retirement System has invested 0% in Epizyme, Inc. (NASDAQ:EPZM). Foresite Capital Ii Ltd Liability Co reported 1.54M shares. California State Teachers Retirement Sys holds 0% of its portfolio in Epizyme, Inc. (NASDAQ:EPZM) for 66,249 shares. First Republic Investment Mngmt Incorporated holds 0% or 14,243 shares. Massachusetts-based Eventide Asset Ltd Liability Co has invested 0.3% in Epizyme, Inc. (NASDAQ:EPZM).

Among 12 analysts covering Epizyme (NASDAQ:EPZM), 11 have Buy rating, 0 Sell and 1 Hold. Therefore 92% are positive. Epizyme had 29 analyst reports since August 6, 2015 according to SRatingsIntel. The company was maintained on Thursday, November 2 by H.C. Wainwright. The firm has “Buy” rating given on Monday, June 5 by Oppenheimer. The stock of Epizyme, Inc. (NASDAQ:EPZM) has “Sector Perform” rating given on Thursday, November 2 by RBC Capital Markets. The stock of Epizyme, Inc. (NASDAQ:EPZM) has “Buy” rating given on Thursday, November 2 by Leerink Swann. The company was maintained on Monday, September 28 by RBC Capital Markets. The firm earned “Buy” rating on Tuesday, May 10 by Mizuho. The stock of Epizyme, Inc. (NASDAQ:EPZM) earned “Buy” rating by SunTrust on Friday, October 27. As per Wednesday, June 7, the company rating was maintained by Cowen & Co. The firm has “Buy” rating given on Tuesday, April 5 by Citigroup. Zacks downgraded the stock to “Buy” rating in Tuesday, August 25 report.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: